Series D funds drive Paracor HeartNet trial
This article was originally published in Clinica
Executive Summary
Paracor Medical, a developer of device-based treatments for heart failure, has closed a series D financing round worth $44.35m. The round was led by new investor Aberdare Ventures; other participants include Montagu Newhall Associates, and existing shareholders Delphi Ventures, Pequot Ventures, InterWest Partners, Alta Partners, DeNovo Ventures, Saratoga Ventures and Palo Alto Investors.